 | | Vol. 14.28 – 28 July, 2022 |
| |
|
|
| Scientists showed that highly invasive and proliferative breast cancer cells frequently exhibited Akt-driven lower expression of the nuclear envelope proteins lamin A/C, leading to increased nuclear deformability that permitted enhanced cell migration through confined environments.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors developed an efficient theranostic platform for breast cancer-specific delivery of lipophilic triphenylphosphonium-modified therapeutic recombinant P53 proteins by breast cancer cell-derived extracellular vesicles.
[Journal of Controlled Release] |
|
|
|
| Researchers showed that catulin was expressed in human breast cancer samples and that its expression correlated with the tumor progression.
[Scientific Reports] |
|
|
|
| To gain insight into epigenetic effectors of the transcriptomes of hormone and bazedoxifene-treated breast cancer cells, the authors evaluated a panel of histone modifications.
[PLoS One] |
|
|
|
| Investigators analyzed the miRnome profile of several human breast cancer cell lines to determine the influence of estrogen receptor silencing previously shown to result in epithelial to mesenchymal transition and enhanced tumor invasion.
[Biochemistry and Biophysics Reports] |
|
|
|
| Scientists explored the function of hsa_circ_0097922 in the tamoxifen resistance of breast cancer. Hsa_circ_0097922, microRNA-876-3p, and alpha-actinin 4 (ACTN4) level were detected by real-time quantitative polymerase chain reaction.
[Clinical and Experimental Pharmacology and Physiology] |
|
|
|
|
| The authors highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.
[Cancer Cell International] |
|
|
|
|
| AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application of Enhertu for the treatment of adult patients in the US with unresectable or metastatic HER2-low breast cancer who have received a prior therapy in the metastatic setting.
[AstraZeneca PLC] |
|
|
|
|
| October 10 – 12, 2022
Lausanne, Switzerland |
|
|
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Hershey College of Medicine – Hershey, Pennsylvania, United States |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
